{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:06:42Z","timestamp":1776179202803,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2628-B-197-001, MOST 110-2923-B-197-001-MY3, MOST 110-2811-B-197-002"],"award-info":[{"award-number":["MOST 110-2628-B-197-001, MOST 110-2923-B-197-001-MY3, MOST 110-2811-B-197-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Aberrant activation of the NLRP3 inflammasome promotes the pathogenesis of many inflammatory diseases. The development of the NLRP3 inflammasome inhibitors from existing drugs for new therapeutic purposes is becoming more important. Candesartan is an angiotensin II receptor antagonist widely used as a blood pressure-lowering drug; however, the inhibitory potential of candesartan on the NLRP3 inflammasome has not yet been investigated. We demonstrated that candesartan significantly inhibited the NLRP3 inflammasome and pyroptosis in macrophages. Mechanistic analysis revealed that candesartan inhibited the expression of NLRP3 and proIL-1\u03b2 by suppressing NF-\u03baB activation and reducing the phosphorylation of ERK1\/2 and JNK1\/2. Candesartan reduced mitochondrial damage and inhibited the NLRP3 inflammasome assembly by suppressing NLRP3 binding to PKR, NEK7 and ASC. In addition, candesartan inhibited IL-1\u03b2 secretion partially through autophagy induction. Furthermore, oral administration of candesartan reduced peritoneal neutrophil influx, NLRP3 and ASC expression in peritoneal cells, and lavage fluid concentrations of active caspase-1, IL-1\u03b2, IL-6 and MCP-1 in uric acid crystal-injected mice. These results indicated that candesartan has board anti-inflammatory effects and has the potential to be repositioned to ameliorate inflammatory diseases or NLRP3-associated complications.<\/jats:p>","DOI":"10.3389\/fimmu.2022.870627","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T05:04:59Z","timestamp":1653023099000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity"],"prefix":"10.3389","volume":"13","author":[{"given":"Wen-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Yun","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Wen","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsien-Ta","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Lung","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg V.","family":"Chernikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Meng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Feng","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.12.007","article-title":"Inflammasome Priming in Sterile Inflammatory Disease","volume":"23","author":"Patel","year":"2017","journal-title":"Trends Mol Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: Mechanism of Action, Role in Disease, and Therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2018.07.076","article-title":"NLRP3 Inflammasome Activation and Lung Fibrosis Caused by Airborne Fine Particulate Matter","volume":"163","author":"Zheng","year":"2018","journal-title":"Ecotoxicol Environ Saf"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008155107","article-title":"Nanoparticles Activate the NLR Pyrin Domain Containing 3 (Nlrp3) Inflammasome and Cause Pulmonary Inflammation Through Release of IL-1\u03b1 and IL-1\u03b2","volume":"107","author":"Yazdi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12296","article-title":"Regulation of Inflammasome Activation","volume":"265","author":"Man","year":"2015","journal-title":"Immunol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 Inflammasome in Cancer and Metabolic Diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171848","article-title":"A New Lead to NLRP3 Inhibition","volume":"214","author":"Lamkanfi","year":"2017","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 Directly Targets the NLRP3 ATP-Hydrolysis Motif for Inflammasome Inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 Closes the Active Conformation of NLRP3 to an Inactive State","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01920","article-title":"Repositioning of the \u03b2-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome","volume":"9","author":"Wong","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.587000","article-title":"Candesartan Cilexetil: An Update","volume":"12","author":"Joost","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1038\/s41598-019-42130-z","article-title":"Glucosamine Inhibits IL-1\u03b2 Expression by Preserving Mitochondrial Integrity and Disrupting Assembly of the NLRP3 Inflammasome","volume":"9","author":"Chiu","year":"2019","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1038\/s41598-017-06647-5","article-title":"A GalNAc\/Gal-Specific Lectin From the Sea Mussel Crenomytilus Grayanus Modulates Immune Response in Macrophages and in Mice","volume":"7","author":"Chernikov","year":"2017","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature15541","article-title":"Caspase-11 Cleaves Gasdermin D for Non-Canonical Inflammasome Signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting Edge: NF-kappaB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100613","article-title":"Cutting Edge: Reactive Oxygen Species Inhibitors Block Priming, But Not Activation, of the NLRP3 Inflammasome","volume":"187","author":"Bauernfeind","year":"2011","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00011-012-0555-2","article-title":"Lipopolysaccharide\/adenosine Triphosphate-Mediated Signal Transduction in the Regulation of NLRP3 Protein Expression and Caspase-1-Mediated Interleukin-1\u03b2 Secretion","volume":"62","author":"Liao","year":"2013","journal-title":"Inflamm Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ni0311-199","article-title":"Mitochondrial Control of the NLRP3 Inflammasome","volume":"12","author":"Kepp","year":"2011","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ Efflux is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature16959","article-title":"NEK7 Is an Essential Mediator of NLRP3 Activation Downstream of Potassium Efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural Mechanism for NEK7-Licensed Activation of NLRP3 Inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature11290","article-title":"Novel Role of PKR in Inflammasome Activation and HMGB1 Release","volume":"488","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.591803","article-title":"Interplay Between NLRP3 Inflammasome and Autophagy","volume":"11","author":"Biasizzo","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.24612","article-title":"Review of Drug Repositioning Approaches and Resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171419","article-title":"Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide Inhibits the Cryopyrin\/Nalp3 Inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: A Review of its Therapeutic Applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast Directly Targets NLRP3 to Treat Inflammasome-Driven Diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/life11080864","article-title":"Repurposing Colchicine in Treating Patients With COVID-19: A Systematic Review and Meta-Analysis","volume":"11","author":"Lien","year":"2021","journal-title":"Life (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16798","article-title":"Anti-Inflammatory Mechanisms and Research Progress of Colchicine in Atherosclerotic Therapy","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 Inflammasome and COVID-19: Activation, Pathogenesis and Therapeutic Strategies","volume":"61","author":"Zhao","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/med.21781","article-title":"NLRP3 Inflammasome in Cardiovascular Diseases: Pathophysiological and Pharmacological Implications","volume":"41","author":"Pellegrini","year":"2021","journal-title":"Med Res Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01254.x","article-title":"Colchicine Inhibits Cationic Dye Uptake Induced by ATP in P2X2 and P2X7 Receptor-Expressing Cells: Implications for its Therapeutic Action","volume":"163","author":"Marques-da-Silva","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/srep32587","article-title":"Colchicine Prevents NSAID-Induced Small Intestinal Injury by Inhibiting Activation of the NLRP3 Inflammasome","volume":"6","author":"Otani","year":"2016","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2550","article-title":"Microtubule-Driven Spatial Arrangement of Mitochondria Promotes Activation of the NLRP3 Inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs Inhibit the NLRP3 Inflammasome and Protect Against Alzheimer's Disease in Rodent Models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-017-1405-z","article-title":"Identification and Validation of Uterine Stimulant Methylergometrine as a Potential Inhibitor of Caspase-1 Activation","volume":"22","author":"Garc\u00eda-La\u00ednez","year":"2017","journal-title":"Apoptosis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765201920180699","article-title":"Candesartan Inhibits Inflammation Through an Angiotensin II Type 1 Receptor Independent Way in Human Embryonic Kidney Epithelial Cells","volume":"91","author":"Yu","year":"2019","journal-title":"Acad Bras Cienc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2019.02.035","article-title":"Suppressive Effects of Type I Angiotensin Receptor Antagonists, Candesartan and Irbesartan on Allergic Asthma","volume":"852","author":"Kim","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/2058738420974900","article-title":"Candesartan Modulates Microglia Activation and Polarization via NF-KappaB Signaling Pathway","volume":"34","author":"Qie","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12802","article-title":"Candesartan Ameliorates Brain Inflammation Associated With Alzheimer's Disease","volume":"24","author":"Torika","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200049","article-title":"Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs","volume":"74","author":"Ihara","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110653","article-title":"Candesartan Could Ameliorate the COVID-19 Cytokine Storm","volume":"131","author":"Elkahloun","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature11729","article-title":"NLRP3 is Activated in Alzheimer's Disease and Contributes to Pathology in APP\/PS1 Mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283314bc7","article-title":"Candesartan Reduces the Innate Immune Response to Lipopolysaccharide in Human Monocytes","volume":"27","author":"Larrayoz","year":"2009","journal-title":"J Hypertens"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1038\/s41467-019-11169-x","article-title":"Hydrogen Peroxide Release by Bacteria Suppresses Inflammasome-Dependent Innate Immunity","volume":"10","author":"Erttmann","year":"2019","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070770","article-title":"Long-Term, High-Dosage Candesartan Suppresses Inflammation and Injury in Chronic Kidney Disease: Nonhemodynamic Renal Protection","volume":"18","author":"Yu","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00276","article-title":"NLRP3 Inflammasome and Inflammatory Bowel Disease","volume":"10","author":"Zhen","year":"2019","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12974-022-02419-9","article-title":"A Selective Inhibitor of the NLRP3 Inflammasome as a Potential Therapeutic Approach for Neuroprotection in a Transgenic Mouse Model of Huntington's Disease","volume":"19","author":"Chen","year":"2022","journal-title":"J Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.870627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T05:05:07Z","timestamp":1653023107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.870627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2022.870627"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.870627","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"article-number":"870627"}}